<DOC>
	<DOCNO>NCT01266005</DOCNO>
	<brief_summary>This open , randomize , parallel study . Subjects Clevudine Entecavir therapy 48 week ( Clevudine : Entecavir = 2:1 ) , subject Complete Response ( HBV DNA negative ALT normal ) follow-up period additional 48 week .</brief_summary>
	<brief_title>A Study Compare Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine Entecavir Chronic HBV Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>1 . Patient old 18 . 2 . Patient HBsAg positive previous 6 month HBV DNA ≥ 1 x 10^5 copies/mL 3 . Patient HBeAg negative . 4 . Patient ALT≥1×ULN . 5 . Patient able give write informed consent prior study start comply study requirement . 1 . Patient currently receive antiviral , immunomodulatory , cytotoxic corticosteroid therapy . 2 . Patient treat interferon previous 6 month . 3 . Patient treat previously clevudine , lamivudine , adefovir , entecavir , telbivudine investigational nucleoside HBV infection . 4 . Patient coinfected HCV , HDV HIV . 5 . Patient evidence ascites , variceal hemorrhage and/or hepatic encephalopathy . 6 . Patient evidence decompensated Liver cirrhosis and/or hepatocellular carcinoma . 7 . Patient history organ transplantation . 8 . Patient treatment nephrotoxicity drug , competitive drug kidney excrete , and/or hepatotoxicity drug previous 2 month screen . 9 . Patient pregnant breastfeeding . 10 . Patient clinically relevant history abuse alcohol drug . 11 . Patient significant immunocompromised , gastrointestinal , renal , hematological , psychiatric , bronchopulmonary , biliary disease exclude asymptomatic GB stone , neurological , cardiac , oncologic , allergic disease medical illness investigator 's opinion might interfere therapy . The patient benign tumor , exclude judge investigator continuation study would interfere tumor . 12 . Patient creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>HBe Ag ( - ) Chronic Hepatitis B</keyword>
</DOC>